Author

P. C. Gokhale

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 5 Organism:human· 5 Approach:statistical model· 5 Assay:bulk RNA-seq· 3 Approach:experimental assay· 2 Assay:whole-exome sequencing· 2 Approach:biophysical modeling· 1 Assay:ChIP-seq· 1

Frequent Co-Authors

D. E. Root· 3 shared A. L. Hong· 2 shared B. A. Leeper· 2 shared B. D. Kynnap· 2 shared C. M. Clinton· 2 shared E. A. Mullen· 2 shared J. S. Boehm· 2 shared K. L. Ligon· 2 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

D. E. Root

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Integrative analysis reveals therapeutic potential of pyrvinium pamoate in Merkel cell carcinoma

J. Yang, J. T. Lim, P. V. Santiago Raj, M. G. Corona, C. Chen, H. Khawaja, Q. Pan, G. D. Paine-Murrieta, R. G. Schnellmann, D. J. Roe, P. C. Gokhale, J. A. DeCaprio, M. Padi

This study identifies pyrvinium pamoate as a potential therapy for Merkel cell carcinoma by targeting Wnt signaling and multiple cancer vulnerabilities.

bioRxiv · Nov 1, 2023Cancer Biology

EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genes

Y. Huang, R. T. Durall, N. M. Luong, H. J. Hertzler, J. Huang, P. C. Gokhale, B. A. Leeper, N. S. Persky, D. E. Root, P. V. Anekal, P. D. Montero Llopis, C. N. David, J. L. Kutok, A. Raimondi, K. Saluja, , C. A. French

This study identifies EZH2 as a dependency in NUT carcinoma, showing that combining EZH2 and BET inhibitors synergistically blocks tumor growth and prolongs survival.

bioRxiv · Aug 15, 2023Cancer Biology

Covalent Disruptor of YAP-TEAD Association Suppresses Defective Hippo Signaling

M. Fan, W. Lu, J. Che, N. P. Kwiatkowski, Y. Gao, H.-S. Seo, S. B. Ficarro, P. C. Gokhale, Y. Liu, E. A. Geffken, J. Lakhani, K. Song, M. Kuljanin, W. Ji, J. Jiang, , N. Gray

This paper develops a covalent inhibitor of the YAP-TEAD complex, demonstrating its ability to suppress Hippo signaling defects and inhibit cancer cell growth.

bioRxiv · May 10, 2022Cancer Biology

Targeting TRIP13 in Wilms Tumor with Nuclear Export Inhibitors

K. Mittal, B. P. Lee, G. W. Cooper, J. Shim, H. C. Jonus, W. J. Kim, M. Doshi, D. Almanza, B. D. Kynnap, A. L. Christie, X. Yang, G. S. Cowley, B. A. Leeper, C. L. Morton, B. Dwivedi, , A. L. Hong

This study identifies XPO1 inhibition with selinexor as a potential therapy for favorable histology Wilms tumors, showing synergy with doxorubicin in preclinical models.

bioRxiv · Feb 23, 2022Cancer Biology

Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition

A. L. Hong, Y.-Y. Tseng, J. A. Wala, W. J. Kim, B. D. Kynnap, M. B. Doshi, G. Kugener, G. J. Sandoval, T. P. Howard, J. Li, X. Yang, M. Tillgren, M. Ghandi, A. Sayeed, R. Deasy, , W. Hahn

This study identifies SMARCB1 loss as critical for RMC survival and shows proteasome inhibition as a potential therapeutic strategy.

bioRxiv · Dec 5, 2018Cancer Biology